MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Role of surface EMG analysis in distinguishing clonic seizures from tremors

    H. Ticku, N. Fotedar (Cleveland, USA)

    Objective: To compare surface EMG characteristics of clonic seizures with tremors. Background: Clonic seizures can clinically mimic tremors. In cases with poor or no EEG…
  • 2022 International Congress

    Deterioration in Wilson’s Disease despite treatment. Are the neuroimaging findings useful as prognostic factor?

    E. Urrea-Mendoza, S. Zaheer, F. Revilla (Greenville, USA)

    Objective: To describe the neuroimaging findings and their importance in the prognosis during the treatment. Additionally, to describe the state of art of the treatment.…
  • 2022 International Congress

    Burden of COVID-19 among patients with Parkinson’s disease and associated clinical outcomes: Evidence from a meta-analysis

    S. Hussain (Brno, Czech Republic)

    Objective: To understand the burden of covid-19 among patients with Parkinson’s disease and associated clinical outcomes. Background: COVID-19 has affected millions of patients around the…
  • 2022 International Congress

    The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

    Objective: To analyze the sensitivity and specificity of the clonidine growth hormone (CGH) to distinguish probable multiple system atrophy (MSA) from pure autonomic failure (PAF),…
  • 2022 International Congress

    The Edmond J. Safra Fellowship in Movement Disorders: A Global Network of Parkinson’s Experts

    R. Dolhun (New York, USA)

    Objective: To train more movement disorder clinician-researchers around the world to meet growing care and research needs in Parkinson’s and related disorders. Background: Care from…
  • 2022 International Congress

    Evaluation of Genetic influence of APOE on Clinical and motor functions among Idiopathic Parkinson’s Disease Patients; A comparative study

    W. Ibrahim, H. Shehata, L. Rashed, A. Sabbah, H. Amer (Cairo, Egypt)

    Objective: We studied the effect of APOE ε4 carriers and non-carriers on clinical and motor functions in patients with IPD Background: The significance of APOE…
  • 2022 International Congress

    Impact of dopamine replacement therapies on MDS-UPDRS II

    F. Nassan, J. Shirvan, M. Yang, T. Dam, J. Wang, N. Maserejian, W. Flanders (Brookline, USA)

    Objective: To estimate the longitudinal effect of different dopamine therapies on the Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale Part II (MDS-UPDRS II) among…
  • 2022 International Congress

    Parkinsonism-hyperpyrexia as a rare consequence of deep brain stimulator malfunction in patients with Parkinson’s disease

    M. Castela, M. Estrada, S. Bruck, E. San Martín, J. álvarez, C. Fernández, J. Carriles, B. Aragoneses, A. Ayala, E. Liébana, B. López, J. Gil, A. Antón, P. Arroyo, AK. Mendoza (Oviedo, Spain)

    Objective: To report two cases of parkinsonism-hyperpyrexia secondary to failure of the deep brain stimulator (DBS) of the subthalamic nucleus (STN) in patients with Parkinson's…
  • 2022 International Congress

    Characteristics and Treatment Response to OnabotulinumtoxinA of Patients From CD-PROBE With Anterocollis Subtype of Cervical Dystonia

    K. Dashtipour, J. Jankovic, D. Charles, S. Mehta, M. Schwartz, M. Sadeghi (Loma Linda, USA)

    Objective: To describe characteristics and treatment response of patients with anterocollis (AC) treated with onabotulinumtoxinA (onabotA). Background: CD-PROBE included onabotA-treated patients with AC, providing an…
  • 2022 International Congress

    A randomized, double-blinded crossover trial of short versus conventional pulse width subthalamic deep brain stimulation in Parkinson’s Disease

    JN. Petry-Schmelzer, L. Schwarz, H. Jergas, P. Reker, J. Steffen, H. Dafsari, J. Baldermann, G. Fink, V. Visser-Vandewalle, T. Dembek, M. Barbe (Cologne, Germany)

    Objective: To compare 4 weeks of STN-DBS with conventional pulse width stimulation (60µs) to 4 weeks of STN-DBS with short pulse width stimulation (30µs) regarding…
  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley